0001209191-23-059558.txt : 20231222
0001209191-23-059558.hdr.sgml : 20231222
20231222161728
ACCESSION NUMBER: 0001209191-23-059558
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231220
FILED AS OF DATE: 20231222
DATE AS OF CHANGE: 20231222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Alder Matthias
CENTRAL INDEX KEY: 0001370820
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40237
FILM NUMBER: 231510032
MAIL ADDRESS:
STREET 1: C/O MICROMET, INC.
STREET 2: 6707 DEMOCRACY BLVD., STE. 505
CITY: BETHESDA
STATE: MD
ZIP: 28017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gain Therapeutics, Inc.
CENTRAL INDEX KEY: 0001819411
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 851726310
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4800 HAMPDEN LANE
STREET 2: SUITE 200
CITY: BETHESDA
STATE: MD
ZIP: 20814
BUSINESS PHONE: (301) 500-1556
MAIL ADDRESS:
STREET 1: 4800 HAMPDEN LANE
STREET 2: SUITE 200
CITY: BETHESDA
STATE: MD
ZIP: 20814
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-20
0
0001819411
Gain Therapeutics, Inc.
GANX
0001370820
Alder Matthias
C/O GAIN THERAPEUTICS, INC.
4800 MONTGOMERY LANE, SUITE 220
BETHESDA
MD
20814
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-12-20
4
M
0
637
A
5492
D
Common Stock
2023-12-21
4
S
0
206
2.46
D
5286
D
Restricted Stock Units
2023-12-20
4
M
0
637
0.00
D
Common Stock
637
7013
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4602 to $2.485 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The RSUs vested 25% on September 20, 2023 and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
/s/ Matthias Alder
2023-12-22